SUNNYVALE, Calif.--LJL Biosystems here announced last week that it has released its new high-throughput screening product, the Analyst, for commercial shipments. The product is expected to enable drug discovery labs to perform multiple assays with increased throughput sensitivity and reduced costs per assay, and is designed to perform 5-10 million assays per year, the company said. The first commercial shipment of the Analyst was to Millennium Pharmaceuticals. LJL CEO Lev Leytes said he believes the new technology will fundamentally change the drug discovery process by providing scientists with a more efficient, less costly assay detection process.
LJL Biosystems Ships Its Analyst HTS Product To Millennium Pharma
Dec 18, 1998